共 120 条
- [1] Vlaar APJ(2022)Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Lancet Respir Med S2213–2600 00297-301
- [2] Witzenrath M(2005)Role of C5a in inflammatory responses Annu Rev Immunol 23 821-852
- [3] van Paassen P(2006)A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways J Immunol 177 4794-4802
- [4] Heunks LMA(2002)Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis Am J Pathol 160 1867-1875
- [5] Mourvillier B(1997)C5a induces tissue factor activity on endothelial cells Thromb Haemost 77 394-398
- [6] de Bruin S(2017)Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition Clin Immunol 180 25-32
- [7] Guo RF(2022)Complement activation in COVID-19 and targeted therapeutic options: a scoping review Blood Rev 588 146-150
- [8] Ward PA(2020)Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis Nature 67 1164-1177
- [9] Ritis K(2021)Clinical features and prognostic factors in Covid-19: a prospective cohort study EBioMedicine 6 6151-6157
- [10] Doumas M(2021)Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection Sci Immunol 116 319-329